Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic LeukemiaCooper Quartermaine, Daniel Addison, Adnan Shaaban et al.|JACC CardioOncology|2023Cited by 107
Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b StudyNirav N. Shah, Talha Munir, Zulfa Omer et al.|Blood|2024Cited by 27
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLLAdam S. Kittai, Jennifer A. Woyach, Ying Huang et al.|Blood Cancer Journal|2025Cited by 12
Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trialZulfa Omer, Wojciech Jurczak, Alexey V. Danilov et al.|Blood|2025Cited by 3
POSTER: CLL-563 Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings From an Ongoing Phase 1a StudyZulfa Omer, Talha Munir, Alexey V. Danilov et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0